| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers P > Headlines for Pfizer Inc. > News item |
Chromos, Pfizer expand cell line collaboration
By Angela McDaniels
Seattle, Jan. 9 - Chromos Molecular Systems Inc. said it has expanded the scope of its collaboration agreement with Pfizer. Under the expanded agreement, Chromos will use its ACE System to develop a cell line for a Pfizer therapeutic protein product candidate.
The parties will also begin a collaborative program to genetically engineer production cell lines.
"Our relationship with Pfizer has been exceptionally productive as evidenced by their expanded commitment to the ACE System," Chromos president and chief executive officer Alistair Duncan said in a company news release.
Under the terms of the expanded agreement, Pfizer will provide funding to support the new programs. Any product candidates produced using the ACE System that Pfizer elects to develop and commercialize will be subject to the terms of Pfizer's existing non-exclusive commercial license, Chromos said.
Chromos and Pfizer entered into an initial collaboration agreement in December 2004. In May 2005, Pfizer took a non-exclusive license to use the ACE System for research, development and manufacturing of its products.
Chromos' proprietary ACE System is a chromosome-based gene delivery and expression platform used to genetically engineer production cell lines with multiple genes in order to improve their performance in a bioreactor. The process may also reduce the cost of producing therapeutic proteins such as monoclonal antibodies, the company said.
Chromos, based in Burnaby, B.C., employs proprietary technology to develop, manufacture and commercialize biological therapies for debilitating diseases.
New York-based Pfizer develops prescription medicines for humans and animals.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.